Antibodies against cancer

Pages: 1 2 3

In the future, you can create immunotoxins methods of genetic engineering. If two genes, one of which encodes the synthesis of monoclonal antibodies, and the other toxin, will be mounted in bacterial or yeast cell, that the proliferation of such hybrids will get immunotoxin in a single bioconstruction in the required amount. Tempting an introduction to tumor (directly or through the lymphatic vessels) of lipoprotein bubbles-liposomes filled cytotoxic antibodies. At a delay of liposomes in tumors of its toxic products tear the wall and get into the cytoplasm of tumor cells. Liposomal biotechnology is now undergoing experimental check.
Another aspect of the therapeutic use of monoclonal antibodies associated with transplantation of donor bone marrow. His transplant recipient with weakened immunoreactivity threatens the development of incompatibility reactions on the part of the entered immunocompetent cells of the donor with respect to the cells of the recipient. This type of immune pathology is called the reaction of the transplant against the host RTGH, its intensity depends on the number of input of donor cells, their degree of HLA differences from the antigens recipient under oppression of its protective resources. It is clear that reaktywnego recipient introduction a large number of incompatible allogeneic lymphoid cells may convene intensive GVHD with unpredictable outcome. But even with a bone marrow transplant from blood relatives development of GVHD noted in 50% of cases.
Controlled GVHD is used for the treatment of acute and chronic leukemia, as "knocking out" sick cells in this case more efficiently than by cytotoxic chemotherapy. GVHD is mediated by T lymphocytes in the bone marrow, in case of need it can be prevented by removing T cells from the bone marrow with specific monoclonal antibodies.
Another way of weakening GVHD - introduction of such antibodies in the recipient to reduce the amount of circulating T cells in the bloodstream. This way may be weakened and the reaction of rejection by allotransplantation of internal organs (kidney, liver, heart). More efficient use of mixture of monoclonal antibodies, including conjugated to A-chain ricin.
As you can see, monoclonal antibodies can be used as independently, being aimed to tumor-associated antigens, or in combination with cellular toxins. Strategy of treatment tactics should be possible smaller antibodies, especially mouse origin, as it is likely the emergence of antiidiotype, or anti-antibodies that destroy the immune weapon against the tumor. The use of monoclonal antibodies for diagnostics for marking antigens of different tumors is invaluable practical value. This approach finally decided the issue of availability of specific cancer cell antigens.